Journal of Stroke | 2019
Cerebrovascular Drug-Eluting Stent versus Bare-Metal Stent in the Treatment of Vertebral Artery Stenosis: A Non-Inferiority Randomized Clinical Trial
Abstract
Drug-eluting coronary stents have been used for patients with vertebral artery stenosis to prevent the occurrence of in-stent restenosis which affects the therapeutic efficacy of angioplasty and stenting. However, the results are inconsistent. A new cerebrovascular sirolimus-eluting stent system (Maurora, Alain Biotechnology Co. Ltd., Beijing, China), different from the Apollo stent systems (Apollo, MicroPort Scientific Corp., Shanghai, China) made of 316L stainless steel, adopts L605 cobalt-chromium alloy that offers a higher yield and has tensile strength characteristics allowing for thinner thickness while maintaining adequate strength and flexibility suitable for a curved artery of the brain, and the sirolimus can reduce the cell proliferation. This trial was to evaluate the safety and efficacy of this new drug-eluting stent. Cerebrovascular Drug-Eluting Stent versus Bare-Metal Stent in the Treatment of Vertebral Artery Stenosis: A Non-Inferiority Randomized Clinical Trial